EODData

MEMBERSHIP REGISTER LOG IN

NYSE, ADCT: Adc Therapeutics Sa

01 Dec 25 11:53
LAST:

4.235

CHANGE:
 0.07		OPEN:
4.260		HIGH:
4.265		ASK:
0.000		VOLUME:
136.8K
CHG(%):
1.51		PREV:
4.300		LOW:
4.160		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
01 Dec 254.2604.2654.1604.235136.8K
28 Nov 254.3904.4204.2654.300254.9K
26 Nov 254.3704.4504.2904.330388.1K
25 Nov 254.3904.4404.2104.390525.1K
24 Nov 254.1004.4204.0404.370971.5K
21 Nov 253.9604.1353.9504.0201.53M
20 Nov 254.1204.2903.9703.990640.1K
19 Nov 253.9904.1503.9224.020636.8K
18 Nov 253.9504.1003.9104.000718.2K
17 Nov 253.9504.1463.9103.970599.1K

PROFILE

Name:Adc Therapeutics Sa
About:ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Sector:Healthcare
Industry:Biotechnology
Address:BiopOle, Epalinges, Switzerland, 1066
Website:https://www.adctherapeutics.com
CUSIP:000886101
CIK:0000061478
ISIN:CH0499880968
FIGI:BBG00Q6Q3QX1

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-2.58 
Forward P/E:-2.99 
PEG Ratio:-0.08 
Price to Sales:6.50 
Price to Book:-2.39 
Profit Margin:-2.20 
Operating Margin:-1.65 
Return on Assets:-0.23 
Return on Equity:0.78 
EPS Ratio:-1.55 
Revenue:77.25M 
Shares:112.5M 
Market Cap:476.43M 

TECHNICAL INDICATORS

MA5:4.332.2%
MA10:4.161.7%
MA20:4.112.9%
MA50:4.132.6%
MA100:3.6216.9%
MA200:2.8449.3%
STO9:56.52
STO14:59.18
RSI14:51.92
WPR14:-32.56
MTM14:0.28
ROC14:0.07 
ATR:0.24 
Week High:4.455.1%
Week Low:4.044.8%
Month High:4.455.1%
Month Low:3.6349.3%
Year High:4.8013.3%
Year Low:1.05303.3%
Volatility:37.02